Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristin Goddard

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
MMWR. Morbidity and Mortality Weekly Report|May 25, 2023
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023Ruth Link-Gelles, Zachary A Weber, Sarah E Reese, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
BMJ (Clinical Research Ed.)|October 3, 2022
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control studyJill M Ferdinands, Suchitra Rao, Brian E Dixon, et al.
MMWR. Morbidity and Mortality Weekly Report|December 29, 2022
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022Mark W Tenforde, Zachary A Weber, Karthik Natarajan, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
The Journal of Infectious Diseases|November 23, 2022
Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022Malini B DeSilva, Patrick K Mitchell, Nicola P Klein, et al.
Vaccine|July 21, 2023
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021Peter J Embi, Matthew E Levy, Palak Patel, et al.
MMWR. Morbidity and Mortality Weekly Report|March 15, 2023
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022Mark W Tenforde, Zachary A Weber, Karthik Natarajan, et al.
The New England Journal of Medicine|September 8, 2021
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care SettingsMark G Thompson, Edward Stenehjem, Shaun Grannis, et al.
MMWR. Morbidity and Mortality Weekly Report|October 20, 2022
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022Amadea Britton, Peter J Embi, Matthew E Levy, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
MMWR. Morbidity and Mortality Weekly Report|May 25, 2023
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023Ruth Link-Gelles, Zachary A Weber, Sarah E Reese, et al.
MMWR. Morbidity and Mortality Weekly Report|March 28, 2024
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024Ruth Link-Gelles, Elizabeth A K Rowley, Malini B DeSilva, et al.
BMJ (Clinical Research Ed.)|October 3, 2022
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control studyJill M Ferdinands, Suchitra Rao, Brian E Dixon, et al.
MMWR. Morbidity and Mortality Weekly Report|December 29, 2022
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022Mark W Tenforde, Zachary A Weber, Karthik Natarajan, et al.
Lancet (London, England)|October 19, 2024
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysisAmanda B Payne, Janet A Watts, Patrick K Mitchell, et al.
The Journal of Infectious Diseases|November 23, 2022
Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022Malini B DeSilva, Patrick K Mitchell, Nicola P Klein, et al.
Vaccine|July 21, 2023
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021Peter J Embi, Matthew E Levy, Palak Patel, et al.
MMWR. Morbidity and Mortality Weekly Report|March 15, 2023
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022Mark W Tenforde, Zachary A Weber, Karthik Natarajan, et al.
The New England Journal of Medicine|September 8, 2021
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care SettingsMark G Thompson, Edward Stenehjem, Shaun Grannis, et al.
MMWR. Morbidity and Mortality Weekly Report|October 20, 2022
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022Amadea Britton, Peter J Embi, Matthew E Levy, et al.
Pageof 9